title: [Prevalence of nonmevalonate and mevalonate pathways for isoprenoid biosynthesis among bacteria of different systematic groups].
abstract: The effect of fosmidomycin and mevinoline, inhibitors of the nonmevalonate and the mevalonate pathway of isoprenoid biosynthesis, respectively, on the growth of 34 anaerobic and 10 aerobic prokaryotic strains was studied. Fosmidomycin at the concentrations used was shown to inhibit the growth of 9 (of 10) representatives of the family Microbacteriaceae, 4 (of 5) strains of Thermoanaerobacter, and 11 (of 12) strains of Clostridium, whereas mevinoline inhibited the growth of lactobacilli (Carnobacterium), methanogenic and sulfate-reducing bacteria insensitive to fosmidomycin. During the late growth phase, four strains of actinobacteria (of nine) accumulate the compound, which, upon oxidation, generates a long-lived free radical; three strains synthesize 2-C-methyl-D-erythritol-2,4-cyclopyrophosphate (MEC). It was concluded that the difference in the sensitivity of the organisms to fosmidomycin and mevinoline might serve as a test to differentiate several representatives of the family Microbacteriaceae. The use of mevinoline for inhibiting methanogens in ecological investigations seems to be promising.
authors.forename: S M
authors.initials: SM
authors.lastname: Trutko
authors.forename: L V
authors.initials: LV
authors.lastname: Dorofeeva
authors.forename: V A
authors.initials: VA
authors.lastname: Shcherbakova
authors.forename: N A
authors.initials: NA
authors.lastname: Chuvil'skaia
authors.forename: K S
authors.initials: KS
authors.lastname: Laurinavichus
authors.forename: V I
authors.initials: VI
authors.lastname: Biniukov
authors.forename: D N
authors.initials: DN
authors.lastname: Ostrovskiĭ
authors.forename: M
authors.initials: M
authors.lastname: Hintz
authors.forename: J
authors.initials: J
authors.lastname: Wiesner
authors.forename: H
authors.initials: H
authors.lastname: Jomaa
authors.forename: V K
authors.initials: VK
authors.lastname: Akimenko
mesh_terms: D001419:Bacteria / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism*; D003013:Clostridium / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D005578:Fosfomycin / Q000031:analogs & derivatives / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D007778:Lactobacillus / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism; D008148:Lovastatin / Q000494:pharmacology; D019638:Methanomicrobiaceae / Q000254:growth & development / Q000378:metabolism; D008798:Mevalonic Acid / Q000378:metabolism*; D013729:Terpenes / Q000378:metabolism*; D046968:Thermoanaerobacter / Q000187:drug effects / Q000254:growth & development / Q000378:metabolism
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013729:Terpenes; D005578:Fosfomycin; C024640:fosmidomycin; D008148:Lovastatin; D008798:Mevalonic Acid